Saint Louis Heart and Vascular
- Type
- Non-covered entity
- Where
- Bridgeton, MO
- Received
- $658,630 in 114 records, 2019 to 2024 ($0 general, $658,630 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | Research payment | 7 | $214,041 |
| 2023 | Research payment | 5 | $145,119 |
| 2021 | Research payment | 13 | $29,632 |
| 2020 | Research payment | 41 | $149,530 |
| 2019 | Research payment | 48 | $120,308 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Research & Development, LLC | 12 | $359,160 | 2023–2024 |
| Bayer Healthcare Pharmaceuticals Inc. | 102 | $299,470 | 2019–2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 114 | $658,630 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-06-25 | Janssen Research & Development, LLC | $8,330 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-06-14 | Janssen Research & Development, LLC | $34,479 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-05-22 | Janssen Research & Development, LLC | $27,907 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-04-26 | Janssen Research & Development, LLC | $41,713 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-03-25 | Janssen Research & Development, LLC | $23,153 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-03-04 | Janssen Research & Development, LLC | $40,612 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2024-01-26 | Janssen Research & Development, LLC | $37,847 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2024 | |
| 2023-12-20 | Janssen Research & Development, LLC | $4,163 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2023 | |
| 2023-12-15 | Janssen Research & Development, LLC | $34,477 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2023 | |
| 2023-11-17 | Janssen Research & Development, LLC | $57,674 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2023 | |
| 2023-10-25 | Janssen Research & Development, LLC | $36,919 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2023 | |
| 2023-09-15 | Janssen Research & Development, LLC | $11,886 | Research payment | Cash or cash equivalent | 70033093AFL3002 | 2023 | |
| 2021-07-19 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-19 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-19 | Bayer Healthcare Pharmaceuticals Inc. | $1,405 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-19 | Bayer Healthcare Pharmaceuticals Inc. | $1,405 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-19 | Bayer Healthcare Pharmaceuticals Inc. | $1,405 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-14 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-07-06 | Bayer Healthcare Pharmaceuticals Inc. | $5,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $689 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2021-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $689 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2021 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-10-22 | Bayer Healthcare Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $559 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-09-16 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-07-14 | Bayer Healthcare Pharmaceuticals Inc. | $4,215 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-07-14 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-07-14 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-07-13 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-06-17 | Bayer Healthcare Pharmaceuticals Inc. | $37,778 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $5,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-05-11 | Bayer Healthcare Pharmaceuticals Inc. | $689 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-05-11 | Bayer Healthcare Pharmaceuticals Inc. | $689 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-05-08 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $3,432 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-21 | Bayer Healthcare Pharmaceuticals Inc. | $2,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-04-08 | Bayer Healthcare Pharmaceuticals Inc. | $11,893 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2020 |
| 2020-04-08 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-04-08 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-04-08 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-03-06 | Bayer Healthcare Pharmaceuticals Inc. | $5,743 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-03-06 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-02-03 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-01-30 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-01-30 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-01-30 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2020-01-30 | Bayer Healthcare Pharmaceuticals Inc. | $2,117 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2020 |
| 2019-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-12-13 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-11-15 | Bayer Healthcare Pharmaceuticals Inc. | $28,647 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-09-09 | Bayer Healthcare Pharmaceuticals Inc. | $5,079 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-09-09 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-09-09 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-09-09 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-09-09 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-21 | Bayer Healthcare Pharmaceuticals Inc. | $1,800 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
| 2019-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-06-11 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-06-11 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-06-11 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-05-20 | Bayer Healthcare Pharmaceuticals Inc. | $1,704 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
| 2019-05-20 | Bayer Healthcare Pharmaceuticals Inc. | $430 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
| 2019-05-06 | Bayer Healthcare Pharmaceuticals Inc. | $2,710 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
| 2019-05-06 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-05-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-05-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-05-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-12 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY 94-8862 ph 3 conventional in diab nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $2,400 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,800 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,800 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,693 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2019 |
| 2019-01-22 | Bayer Healthcare Pharmaceuticals Inc. | $1,146 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
| 2019-01-22 | Bayer Healthcare Pharmaceuticals Inc. | $960 | Research payment | Cash or cash equivalent | Non-Covered | Vericiguat in HFpEF | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bridgeton, MO, county St. Louis County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Bridgeton, MO | County St. Louis County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 11,369 | 995,569 | 6,191,814 |
| Population, 2020 census P1 | 11,445 | 1,004,125 | 6,154,913 |
| Median age B01002 | 40.9 | 40.3 | 39.0 |
| Under 18 B01001 | 21.8% | 22.0% | 22.3% |
| 65 and over B01001 | 21.5% | 19.1% | 17.9% |
| Households B11001 | 4,747 | 413,849 | 2,508,227 |
| Foreign born B05002 | 13.9% | 8.4% | 4.5% |
| Median household income B19013 | $72,005 | $82,936 | $70,702 |
| Median family income B19113 | $83,153 | $110,950 | $91,360 |
| Per capita income B19301 | $39,809 | $51,977 | $39,695 |
| Poverty rate B17001 | 11.5% | 9.8% | 12.6% |
| Unemployment rate B23025 | 3.2% | 4.3% | 4.0% |
| Civilian labor force B23025 | 5,774 | 521,387 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.2 | 23.1 | 23.5 |
| Bachelor's degree or higher B15003 | 36.0% | 47.4% | 32.4% |
| Housing units B25001 | 5,066 | 446,192 | 2,825,287 |
| Owner-occupied B25003 | 63.1% | 69.2% | 68.1% |
| Renters B25003 | 36.9% | 30.8% | 31.9% |
| Median home value B25077 | $237,700 | $276,800 | $230,300 |
| Median gross rent B25064 | $1,172 | $1,209 | $1,033 |
| White, not Hispanic B03002 | 55.8% | 61.4% | 76.3% |
| Black B03002 | 23.7% | 24.0% | 10.9% |
| Hispanic or Latino B03002 | 13.8% | 3.9% | 5.2% |
| Asian B03002 | 2.7% | 4.9% | 2.1% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bridgeton, MO.
Comments